Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06397911 · ClinicalTrials.gov registry record · Phase 2
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Oneness Biotech Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 16
- Study locations
NCT06397911: Recruiting Phase 2 study of Atopic Dermatitis, sponsored by Oneness Biotech Co..
NCT06397911 is a Phase 2 study of Atopic Dermatitis that is actively recruiting participants, run by Oneness Biotech Co.. The registered enrollment target is 90 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (85% lower). The trial reports 16 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06397911, a Phase 2 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Oneness Biotech Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG FB825
Study Locations (16)
Other
- Kaohsiung Chang Gung Memorial Hospital - Kaohsiung City
- Kaohsiung Veterans General Hospital - Kaohsiung City
- Linkou Chang Gung Memorial Hospital - New Taipei City
- Taipei Medical University-Shuang Ho Hospital - New Taipei City
- China Medical University Hospital - Taichung
- National Cheng Kung University Hospital - Tainan
- National Taiwan University Hospital - Taipei
- Taipei Mackay Memorial Hospital - Taipei
- Taipei Veterans General Hospital - Taipei
- Tri-Service General Hospital - Taipei
California
- First OC Dermatology - Fountain Valley
- Center for Dermatology Clinical Research, Inc. - Fremont
- California Allergy and Asthma Medical Group - Los Angeles
- University of California, Davis Health, Department of Dermatology - Sacramento
Texas
- UT Health Science Houston - Bellaire
- Center for Clinical Studies - Webster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What NCT06397911 shows while recruiting
NCT06397911 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06397911 lists 16 locations in 3 states (Other, California, Texas).
Frequently Asked Questions
What is clinical trial NCT06397911 about?
NCT06397911 is a clinical study titled "Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis". This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.
What is the current status of trial NCT06397911?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-08-08. Estimated completion is 2026-06-30.
What conditions does trial NCT06397911 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06397911?
The interventions under investigation include: Placebo (DRUG), FB825 (DRUG).
Who is sponsoring clinical trial NCT06397911?
This trial is sponsored by Oneness Biotech Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06397911 being conducted?
This trial has 16 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06397911's enrollment target sits among peer trials
90 90th of 150 higher than 58 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI